[go: up one dir, main page]

MX2012004157A - 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. - Google Patents

8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.

Info

Publication number
MX2012004157A
MX2012004157A MX2012004157A MX2012004157A MX2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A MX 2012004157 A MX2012004157 A MX 2012004157A
Authority
MX
Mexico
Prior art keywords
treatment
pyrido
pyrimidin
aryl
ones
Prior art date
Application number
MX2012004157A
Other languages
English (en)
Inventor
Benedikt Vollrath
Sergio G Duron
David Campbell
Warren Wade
Original Assignee
Afraxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afraxis Inc filed Critical Afraxis Inc
Publication of MX2012004157A publication Critical patent/MX2012004157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen aquí inhibidores de PAK y métodos de utilización de inhibidores de PAK para el tratamiento de trastornos del sistema nervioso central tales como trastornos neurosiquiátricos.
MX2012004157A 2009-10-09 2010-10-08 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. MX2012004157A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25026209P 2009-10-09 2009-10-09
US35305410P 2010-06-09 2010-06-09
PCT/US2010/052106 WO2011044535A2 (en) 2009-10-09 2010-10-08 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2012004157A true MX2012004157A (es) 2012-08-03

Family

ID=43857425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004157A MX2012004157A (es) 2009-10-09 2010-10-08 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.

Country Status (16)

Country Link
US (2) US8372970B2 (es)
EP (1) EP2486037A4 (es)
JP (1) JP2013507395A (es)
KR (1) KR20120104200A (es)
CN (1) CN102648200A (es)
AR (1) AR078609A1 (es)
AU (1) AU2010303218A1 (es)
BR (1) BR112012007935A2 (es)
CA (1) CA2776770A1 (es)
EA (1) EA201270498A1 (es)
IL (1) IL219078A0 (es)
MX (1) MX2012004157A (es)
PH (1) PH12012500692A1 (es)
TW (1) TW201118095A (es)
WO (1) WO2011044535A2 (es)
ZA (1) ZA201202688B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20110217280A1 (en) * 2007-12-19 2011-09-08 Vollrath Benedikt Methods for treating neuropsychiatric conditions
US20100317715A1 (en) * 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
EP2504011A4 (en) * 2009-11-23 2013-07-31 Afraxis Inc METHOD FOR TREATING EASY COGNITIVE IMPAIRMENT
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
US8912203B2 (en) 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2582374A4 (en) * 2010-06-16 2014-03-19 Afraxis Holdings Inc METHOD FOR TREATING NERVOUS ELEMENTS
RU2013149800A (ru) * 2011-04-08 2015-05-20 Афраксис Холдингз, Инк. 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения расстройств нервной системы и рака
SG11201401996TA (en) * 2011-11-04 2014-05-29 Afraxis Holdings Inc Pak inhibitors for the treatment of fragile x syndrome
BR112014020173A8 (pt) 2012-03-16 2017-07-11 Hoffmann La Roche Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
WO2014056082A1 (en) * 2012-10-12 2014-04-17 University Of Prince Edward Island Method for measuring symptoms of autism spectrum disorders and comorbid conditions
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
WO2015011252A1 (en) * 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Pyrimidine-pyridinone serine/threonine kinase inhibitors
EP2905024A1 (en) 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
TWI511868B (zh) * 2014-10-27 2015-12-11 Nat Univ Tsing Hua A Method for Instantaneous Measurement of Local Permeability Coefficient of Injection Molding
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
WO2017192228A1 (en) * 2016-05-06 2017-11-09 Albert Einstein College Of Medicine, Inc. Pak1 inhibitors and uses thereof
CA3191481A1 (en) 2017-01-20 2018-07-26 Polaris Industries Inc. Diagnostic systems and methods of a continuously variable transmission
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业（江苏）有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
CN110914267B (zh) * 2017-07-19 2022-07-12 江苏奥赛康药业有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
CN116271206B (zh) * 2023-04-10 2025-02-25 温州市工业科学研究院 一种镓卟啉配合物/丝素蛋白抗菌敷料及其制作方法
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia
CN118084902B (zh) * 2024-01-16 2024-10-29 赣南师范大学 2-氨基噻唑嘧啶并吡啶酮类化合物或药学上可接受的盐或立体异构体及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
CA2394650A1 (en) 1999-12-17 2001-06-21 Chi B. Vu Novel heterocycles
DZ3308A1 (fr) * 2000-03-06 2001-09-27 Warner Lambert Co Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines
WO2001098775A1 (en) * 2000-06-16 2001-12-27 The Board Of Trustees Of The University Of Arkansas Regulation of the p21 gene and uses thereof
CA2420122A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
CA2542105C (en) 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
EP1846403A1 (en) 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2076513A1 (en) 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
CN101535308A (zh) * 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
TW201118095A (en) 2011-06-01
AR078609A1 (es) 2011-11-23
BR112012007935A2 (pt) 2019-09-24
JP2013507395A (ja) 2013-03-04
EP2486037A2 (en) 2012-08-15
WO2011044535A3 (en) 2011-08-18
EA201270498A1 (ru) 2012-11-30
US8372970B2 (en) 2013-02-12
KR20120104200A (ko) 2012-09-20
US20130035335A1 (en) 2013-02-07
WO2011044535A2 (en) 2011-04-14
ZA201202688B (en) 2014-10-29
PH12012500692A1 (en) 2012-11-12
CN102648200A (zh) 2012-08-22
US20120270866A1 (en) 2012-10-25
IL219078A0 (en) 2012-06-28
AU2010303218A1 (en) 2012-05-10
EP2486037A4 (en) 2013-01-16
CA2776770A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
MX2012004157A (es) 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
MX2013011518A (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
EP2580213A4 (en) 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
EP2580214A4 (en) 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011156780A3 (en) 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
LT2945632T (lt) Heterociklo-pakeisti-[1,2,4]triazolo[1,5-c]chinazolin-5-amino junginiai, tinkami centrinės nervų sistemos sutrikimų gydymui arba prevencijai
CU24522B1 (es) PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS
WO2011156786A3 (en) 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
BR112013019354A2 (pt) derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inibidores de fosfodiesterases
WO2011156775A3 (en) 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
GT201300206A (es) Imidazo(5,1-f)(1,2,4)triazinas para el tratamiento de transtornos neurológicos
UY33801A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
PH12014500995A1 (en) Pak inhibitors for the treatment of cell proliferative disorders
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
BRPI0909628A2 (pt) compostos de azaindol para o tratamento de distúrbios do sistema nervosos central
MX2014006015A (es) Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
PE20150965A1 (es) Azaindolinas
MX2014014808A (es) Compuestos triciclicos como inhibidores de kat ii.
BR112014014560A8 (pt) subpopulação de monócitos humanos para tratamento de lesões do sistema nervoso central
IL244619A0 (en) Pyrido[3-b,4]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
IL229791A0 (en) Indoleamine derivatives for the treatment of diseases of the central nervous system

Legal Events

Date Code Title Description
FA Abandonment or withdrawal